Oracle (ORCL) — The Transparent Read
41/100Cautiously Bearish$147.76 · downtrend
This is a falling knife resting on a cushion. The trend is clearly down — below both major moving averages with a death cross and negative MACD — so this is not a place to chase as a long-term turnaround. But the confluence of oversold RSI, a defended support level at $145.20, and a historically favorable macro base rate sets up a credible near-term bounce. My lean: expect a relief rally off support, but treat it as a tactical move within a damaged downtrend, not a trend reversal. The weight of evidence remains cautiously bearish until the bigger structural levels are reclaimed.
ORCL key levels
Show Your Work — every point in ORCL's score
The score starts at 50, then each signal below adds or subtracts points. No black box.
| Signal | Type | Points |
|---|---|---|
| Below 200-day MA Price is below its 200-day average — long-term trend is down. | technical | -8 |
| Below 50-day MA Trading below the 50-day average — medium-term momentum is weak. | technical | -5 |
| Death cross 50-day average is below the 200-day (death cross). | technical | -4 |
| RSI oversold RSI is 29 — oversold, potential for a bounce. | technical | +6 |
| MACD negative MACD is below its signal line — momentum is fading. | technical | -5 |
| Near support Holding near support around $145.20. | technical | +4 |
| Macro regime base rate In 38 past periods like today (Rising inflation + Steady Fed), this stock was higher 90d later 63% of the time (median +3.1%). Historically favorable. | macro | +2.63 |
Macro regime base rate
Today's regime: Rising inflation + Steady Fed
In 38 past periods that looked like today, ORCL was higher 90 days later 63% of the time (median move 3.1%). Confidence: high.
The read
ORCL Hammered Into Oversold Territory — Bouncing on Support or Just Resting?
Bull case. The stock is sitting on key support at $145.20 with RSI at 29, deep in oversold territory where mean-reversion bounces often start. The macro regime (rising inflation + steady Fed) is historically favorable here — in 38 analogous periods ORCL was higher 90 days later 63% of the time, with a median gain of +3.1% (high confidence). For dip-hunters, this is the kind of capitulation zone that can mark a near-term floor.
Bear case. The bigger picture is ugly. Price at $147.76 is miles below both the 50-day MA ($188.46) and 200-day MA ($201.39), and a death cross is in effect — the textbook signature of an entrenched downtrend. MACD histogram at -6.47 shows momentum still fading, not turning. Resistance is a distant $250.25, meaning there's enormous overhead supply between here and any meaningful recovery. The composite score of 40.6 (Cautiously Bearish) reflects a market still firmly in sellers' hands.
What would change my mind. A decisive close below $145.20 support would invalidate the bounce thesis and open the door to further downside. On the flip side, a reclaim of the 50-day MA at $188.46 — with MACD crossing back positive — would flip the medium-term read from bearish to constructive.
ORCL — frequently asked
Is ORCL a buy according to Tallyread?
Tallyread does not give buy or sell recommendations. It shows a transparent 41/100 read for Oracle (ORCL), conditioned on today's macro regime, with every scoring input itemized so you can judge for yourself. This is not financial advice.
How is ORCL's Tallyread score calculated?
The 41/100 score starts at 50, then adds and subtracts named technical and macro signals — each shown with its point value and a one-line reason in the "Show Your Work" table on this page. Nothing is hidden in a black box.
How does today's Fed-and-inflation regime affect ORCL?
In 38 past periods whose macro regime matched today's (Rising inflation + Steady Fed), ORCL was higher 90 days later 63% of the time, with a median move of 3.1%. Confidence: high.
Want a fresh read on ORCL with the live chart and macro tape?
Run a live ORCL read →Last analyzed 2026-06-30 · Data source: tiingo. See the public scorecard and methodology.
This is a historical and technical read for informational and educational purposes only — not financial advice, and not a recommendation to buy or sell ORCL. Markets are uncertain; do your own research.